Joshua Meyers

Joshua Meyers

Auto-generated profile, based on publicly available information

Joshua Meyers

BenevolentAI (United Kingdom)

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2021 in Drug Discovery Today
Verified
Journal Article
Open access
JMJoshua Meyers
Joshua Meyers
BFBenedek Fabian
Benedek Fabian
NBNathan Brown
Nathan Brown
Molecular design strategies are integral to therapeutic progress in drug discovery. Computational approaches for de novo molecular design have been developed over the past three decades and, recently, thanks in part to advances in machine learning (ML) and artificial intelligence (AI), the drug discovery field has gained practical experience. Here, we review these learnings and present de novo approaches according to the coarseness of their molecular representation: that is, whether molecular design is modeled on an atom-based, fragment-based, or reaction-based paradigm. Furthermore, we emphasize the value of strong benchmarks, describe the main challenges to using these methods in practice, and provide a viewpoint on further opportunities for exploration and challenges to be tackled in the upcoming years.

30 August 2016 in Future Medicinal Chemistry
Verified
Journal Article
Open access
JMJoshua Meyers
Joshua Meyers
MCMichael Carter
Michael Carter
NMN Yi Mok
N Yi Mok
NBNathan Brown
Nathan Brown
Aim: Many medicinal chemistry-relevant structures and core scaffolds tend toward geometric planarity, which hampers the optimization of physicochemical properties desirable in drug-like molecules. ...

5 February 2020 in Journal of Chemical Information and Modeling
Verified
Journal Article
Open access
MSMartin Simonovsky
Martin Simonovsky
JMJoshua Meyers
Joshua Meyers
Protein pocket matching, or binding site comparison, is of importance in drug discovery. Identification of similar binding pockets can help guide efforts for hit finding, understanding polypharmacology and characterization of protein function. The design of pocket matching methods has traditionally involved much intuition, and has employed a broad variety of algorithms and representations of the input protein structures. We regard the high heterogeneity of past work and the recent availability of large-scale benchmarks as an indicator that a data-driven approach may provide a new perspective. We propose DeeplyTough, a convolutional neural network that encodes a three-dimensional representation of protein pockets into descriptor vectors that may be compared efficiently in an alignment-free manner by computing pairwise Euclidean distances. The network is trained with supervision: (i) to provide similar pockets with similar descriptors, (ii) to separate the descriptors of dissimilar pockets by a minimum margin, and (iii) to achieve robustness to nuisance variations. We evaluate our method using three large-scale benchmark datasets, on which it demonstrates excellent performance for held-out data coming from the training distribution and competitive performance when the trained network is required to generalize to datasets constructed independently. DeeplyTough is available at https://github.com/BenevolentAI/DeeplyTough.

12 July 2017 in Chemical Communications
Verified
Journal Article
Open access
PDF file
Louis AllottLouis Allott
Louis Allott
CPChiara Da Pieve
Chiara Da Pieve
JMJ. Meyers
J. Meyers
TST. Spinks
T. Spinks
DCD. M. Ciobota
D. M. Ciobota
GSG. Smith
G. Smith
The future of 89Zr-based immuno-PET is reliant upon the development of new chelators with improved stability compared to the currently used deferoxamine (DFO).

16 November 2018 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Open access
JMJoshua Meyers
Joshua Meyers
NCNicola E. A. Chessum
Nicola E. A. Chessum
SASalyha Ali
Salyha Ali
NMN. Yi Mok
N. Yi Mok
BWBirgit Wilding
Birgit Wilding
MCMatthew D. Cheeseman
Matthew D. Cheeseman
Polypharmacology is often a key contributor to the efficacy of a drug, but is also a potential risk. We investigated two hits discovered via a cell-based phenotypic screen, the CDK9 inhibitor CCT250006 (1) and the pirin ligand CCT245232 (2), to establish methodology to elucidate their secondary protein targets. Using computational pocket-based analysis, we discovered intrafamily polypharmacology for our kinase inhibitor, despite little overall sequence identity. The interfamily polypharmacology of 2 with B-Raf was used to discover a novel pirin ligand from a very small but privileged compound library despite no apparent ligand or binding site similarity. Our data demonstrates that in areas of drug discovery where intrafamily polypharmacology is often an issue, ligand dissimilarity cannot necessarily be used to assume different off-target profiles and that understanding interfamily polypharmacology will be important in the future to reduce the risk of idiopathic toxicity and in the design of screening libraries.

6 December 2016 in Journal of Cheminformatics
Verified
Journal Article
Open access
PDF file
JMJoshua Meyers
Joshua Meyers
NBNathan Brown
Nathan Brown
JBJulian Blagg
Julian Blagg
Analysis of the 3D structures of protein–ligand binding sites can provide valuable insights for drug discovery. Binding site comparison (BSC) studies can be employed to elucidate the function of orphan proteins or to predict the potential for polypharmacology. Many previous binding site analyses only consider binding sites surrounding an experimentally observed bound ligand. To encompass potential protein–ligand binding sites that do not have ligands known to bind, we have incorporated fpocket cavity detection software and assessed the impact of this inclusion on BSC performance. Using fpocket, we generated a database of ligand-independent potential binding sites and applied the BSC tool, SiteHopper, to analyze similarity relationships between protein binding sites. We developed a method for clustering potential binding sites using a curated dataset of structures for six therapeutically relevant proteins from diverse protein classes in the protein data bank. Two clustering methods were explored; hierarchical clustering and a density-based method adept at excluding noise and outliers from a dataset. We introduce circular plots to visualize binding site structure space. From the datasets analyzed in this study, we highlight a structural relationship between binding sites of cationic trypsin and prothrombin, protein targets known to bind structurally similar small molecules, exemplifying the potential utility of objectively and holistically mapping binding site space from the structural proteome. We present a workflow for the objective mapping of potential protein–ligand binding sites derived from the currently available structural proteome. We show that ligand-independent binding site detection tools can be introduced without excessive penalty on BSC performance. Clustering combined with intuitive visualization tools can be applied to map relationships between the 3D structures of protein binding sites.